chemotherapy – Medxy AI

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY 09/16/2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.

Clinical Updates Wellness & Lifestyle

LEAP-015: Evaluating Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy Alone in Advanced Gastroesophageal Adenocarcinoma

By MedXY 08/07/2025

The LEAP-015 phase III trial found that adding lenvatinib and pembrolizumab to chemotherapy marginally improved progression-free survival but not overall survival in advanced gastroesophageal adenocarcinoma, with increased toxicity.

Clinical Updates Wellness & Lifestyle

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

By MedXY 08/03/2025

The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.

Clinical Updates Wellness & Lifestyle

Zanidatamab Plus Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastro-Oesophageal Adenocarcinoma: Clinical Efficacy and Safety Insights from a Phase 2 Study

By MedXY 08/03/2025

Zanidatamab combined with chemotherapy shows promising efficacy and manageable safety in first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma, with durable responses and improved survival outcomes.

Clinical Updates Wellness & Lifestyle

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

By MedXY 08/01/2025

A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.